theliatinib (HMPL-309) / Hutchmed - LARVOL DELTA

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=33; Terminated; Sponsor: Hutchison Medipharma Limited; N=66 ➔ 33; Trial completion date: Jun 2019 ➔ Dec 2018; Recruiting ➔ Terminated; Trial primary completion date: Jun 2019 ➔ Dec 2018; the change of clinical development plan

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=66; Recruiting; Sponsor: Hutchison Medipharma Limited; Trial completion date: Mar 2019 ➔ Jun 2019; Trial primary completion date: Dec 2018 ➔ Jun 2019

Clinical • Trial completion date • Trial primary completion date